Download PDF
Am J Perinatol 2022; 39(S 01): S68-S72
DOI: 10.1055/s-0042-1758857
Original Article

Milk-Based Bionutrient Trials to Improve Outcomes in Preterm Infants: Challenges and Opportunities

Nicholas D. Embleton
1   Newcastle Hospitals National Health Service Trust, Newcastle upon Tyne, United Kingdom
2   Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
,
Janet E. Berrington
2   Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
3   Translational Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective Bionutrients (or immunonutrients) are dietary components present in milk, or supplements that could be added to milk diets, that impact health and disease. With few exceptions, most of these are present in human breastmilk and the majority are also present in amniotic fluid.

Study Design Bionutrients can be proteins and peptides including enzymes, hormones, immunoglobulins, and growth factors and can also be molecules such as human milk oligosaccharides, amino acids, or lipids such as docosahexaenoic acid. Many of these have ancient origins, are found in other species, and existed before mammalian lactation evolved. Bionutrients may act in diverse ways when administered enterally: they may impact gut bacterial communities or epithelial cell metabolism, or they may pass into the lamina propria where they interact with the gut and systemic immune systems. Clinical trials have often used bovine analogs such as lactoferrin or may use artificially synthesized or recombinant compounds including insulin, bile salt stimulated lipase, or oligosaccharides.

Results Challenges arise because the bioactivity of proteins, such as lactoferrin, may be affected by processing and pasteurization meaning that the impacts of commercial products may differ. The challenge of determining the optimal bioactivity of any single preparation may be even greater in complex compounds such as milk fat globule membrane. It is also possible that bioactivity is affected by the milk matrix, that is, may differ between formula and human milk.

Conclusion Finally, it is important to appreciate that nutrients do not function in isolation, and most will not act like drugs, that is, they may take several days or longer to exert an affect.

Key Points

  • Breastmilk contains high concentrations of bionutrients and provides more than macro- and micronutrients.

  • Bionutrients can be proteins (e.g. enzymes, hormones, or immunoglobulins) or molecules (e.g. human milk oligosaccharides or amino acids).

  • Bionutrients can be added to milk feeds but high quality trials are needed.

Keywords

bionutrients - necrotizing enterocolitis - chronic lung disease

Note

As authors of the abstract, we grant to the MCA EVENTS ORGANIZER the nonexclusive rights of use of this abstract, including tables and illustrations, for the purpose of publication, also in extract form, in printed and electronic media published by the Thieme Group and other publishers. The abstract, including any tables and figures, is free of exclusive third-party usage rights.




Publication History

Article published online:
05 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Embleton ND, Wood CL, Pearce MS, Brunskill G, Grahame V. Early diet in preterm infants and later cognition: 10-year follow-up of a randomized controlled trial. Pedia Res 2021; 89: 1442-1446
    CrossrefPubMedGoogle Scholar
  • 2 Embleton ND. Early nutrition and later outcomes in preterm infants. World Rev Nutr Diet 2013; 106: 26-32
    CrossrefPubMedGoogle Scholar
  • 3 Tinnion R, Gillone J, Cheetham T, Embleton N. Preterm birth and subsequent insulin sensitivity: a systematic review. Arch Dis Child 2014; 99 (04) 362-368
    CrossrefPubMedGoogle Scholar
  • 4 Embleton ND. Fifteen-minute consultation: ABCDE approach to nutritional assessment in preterm infants. Arch Dis Child Educ Pract Ed 2022; 107 (05) 314-319
    CrossrefPubMedGoogle Scholar
  • 5 Power ML, Schulkin J. Maternal regulation of offspring development in mammals is an ancient adaptation tied to lactation. Appl Transl Genomics 2013; 2 (01) 55-63
    CrossrefPubMedGoogle Scholar
  • 6 Demmelmair H, Prell C, Timby N, Lönnerdal B. Benefits of lactoferrin, osteopontin and milk fat globule membranes for infants. Nutrients 2017; 9 (08) 817
    CrossrefPubMedGoogle Scholar
  • 7 Granger CL, Embleton ND, Palmer JM, Lamb CA, Berrington JE, Stewart CJ. Maternal breastmilk, infant gut microbiome and the impact on preterm infant health. Acta Paediatr 2021; 110 (02) 450-457
    CrossrefPubMedGoogle Scholar
  • 8 Sproat T, Payne RP, Embleton ND, Berrington J, Hambleton S. T cells in preterm infants and the influence of milk diet. Front Immunol 2020; 11: 1035
    CrossrefPubMedGoogle Scholar
  • 9 Shah PS, Shah VS, Kelly LE. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 4 (04) CD004339
    PubMedGoogle Scholar
  • 10 Hackam DJ, Sodhi CP, Good M. New insights into necrotizing enterocolitis: From laboratory observation to personalized prevention and treatment. J Pediatr Surg 2019; 54 (03) 398-404
    CrossrefPubMedGoogle Scholar
  • 11 Mank E, Sáenz de Pipaón M, Lapillonne A. et al. Efficacy and safety of enteral recombinant human insulin in preterm infants. JAMA Pediatrics 2022 Accessed November 10, 2022 at: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2789461
    PubMedGoogle Scholar
  • 12 Bode L. Human milk oligosaccharides in the prevention of necrotizing enterocolitis: a journey from in vitro and in vivo models to mother-infant cohort studies. Front Pediatr 2018; 6 (December): 385
    CrossrefPubMedGoogle Scholar
  • 13 Autran CA, Kellman BP, Kim JH. et al. Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in preterm infants. Gut 2018; 67 (06) 1064-1070
    CrossrefPubMedGoogle Scholar
  • 14 Masi A, Embleton N, Lamb C, Young G, Granger C, Najera J. et al. Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut 2020; 70 (12) 2273-2282
    CrossrefPubMedGoogle Scholar
  • 15 Hellström A, Nilsson AK, Wackernagel D. et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021; 175 (04) 359-367
    CrossrefPubMedGoogle Scholar
  • 16 Casper C, Carnielli VP, Hascoet JM. et al. rhBSSL improves growth and LCPUFA absorption in preterm infants fed formula or pasteurized breast milk. J Pediatr Gastroenterol Nutr 2014; 59 (01) 61-69
    CrossrefPubMedGoogle Scholar
  • 17 Casper C, Hascoet JM, Ertl T. et al. Recombinant bile salt-stimulated lipase in preterm infant feeding: a randomized phase 3 study. PLoS One 2016; 11 (05) e0156071
    CrossrefPubMedGoogle Scholar
  • 18 Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP. Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013; 18 (03) 143-149
    CrossrefPubMedGoogle Scholar
  • 19 Griffiths J, Jenkins P, Vargova M. et al. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. Lancet 2019; 6736 (18) 1-11
    PubMedGoogle Scholar
  • 20 Lönnerdal B, Du X, Jiang R. Biological activities of commercial bovine lactoferrin sources. Biochem Cell Biol 2021; 99 (01) 35-46
    CrossrefPubMedGoogle Scholar
  • 21 Embleton ND, Berrington JE, Dorling J. et al. Mechanisms affecting the gut of preterm infants in enteral feeding trials. Front Nutr 2017; 4 (May): 14
    CrossrefPubMedGoogle Scholar
  • 22 Embleton ND, Berrington JE. Clinical trials of lactoferrin in the newborn: effects on infection and the gut microbiome. Nestle Nutrition Institute Workshop Ser. 2020; 94: 141-151
    CrossrefPubMedGoogle Scholar